H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (Disulfide bond between Cys2 and Pen7)

Modify Date: 2024-01-02 16:22:44

H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (Disulfide bond between Cys2 and Pen7) structure	Common Name	H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (Disulfide bond between Cys2 and Pen7)
	CAS Number	103429-32-9	Molecular Weight	1104.304
	Density	1.5±0.1 g/cm3	Boiling Point	N/A
	Molecular Formula	C₅₁H₆₉N₁₃O₁₁S₂	Melting Point	N/A
	MSDS	Chinese USA	Flash Point	N/A

Use of H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (Disulfide bond between Cys2 and Pen7)

CTAP is a potent, highly selective, and brain penetrant μ opioid receptor antagonist (IC50=3.5 nM) and displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID)[1].

Name	ctap
Synonym	More Synonyms

Description	CTAP is a potent, highly selective, and brain penetrant μ opioid receptor antagonist (IC50=3.5 nM) and displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID)[1].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Opioid Receptor Signaling Pathways >> Neuronal Signaling >> Opioid Receptor Research Areas >> Neurological Disease
Target	IC50: 3.5 nM (μ opioid receptor) IC50: 4500 nM (δ opioid receptor)[1]
References	[1]. Mitchell J Bartlett, et al. Highly-selective µ-opioid Receptor Antagonism Does Not Block L-DOPA-induced Dyskinesia in a Rodent Model.BMC Res Notes

Density	1.5±0.1 g/cm3
Molecular Formula	C₅₁H₆₉N₁₃O₁₁S₂
Molecular Weight	1104.304
Exact Mass	1103.468140
PSA	461.79000
LogP	0.44
Index of Refraction	1.699
Storage condition	-20°C

MSDS(Chinese)

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes	Xi
RIDADR	NONH for all modes of transport
WGK Germany	3.0

D-Phe-L-Cys-L-T...

CAS#:863443-56-5

H-D-Phe-Cys-Tyr...

CAS#:103429-32-9

Literature: Journal of Medicinal Chemistry, , vol. 29, # 11 p. 2370 - 2375

Boc-D-Trp-OH

CAS#:5241-64-5

H-D-Phe-Cys-Tyr...

CAS#:103429-32-9

Literature: Journal of Medicinal Chemistry, , vol. 43, # 4 p. 569 - 580

(R)-2-((tert-bu...

CAS#:104323-41-3

H-D-Phe-Cys-Tyr...

CAS#:103429-32-9

Literature: Journal of Medicinal Chemistry, , vol. 43, # 4 p. 569 - 580

Boc-Thr(Bzl)-OH

CAS#:15260-10-3

H-D-Phe-Cys-Tyr...

CAS#:103429-32-9

Literature: Journal of Medicinal Chemistry, , vol. 43, # 4 p. 569 - 580

Boc-Arg(Tos)-OH

CAS#:13836-37-8

H-D-Phe-Cys-Tyr...

CAS#:103429-32-9

Literature: Journal of Medicinal Chemistry, , vol. 43, # 4 p. 569 - 580

Precursor 5
CAS#:863443-56-5 D-Phe-L-Cys-L-T... CAS#:5241-64-5 Boc-D-Trp-OH CAS#:104323-41-3 (R)-2-((tert-bu... CAS#:15260-10-3 Boc-Thr(Bzl)-OH
CAS#:13836-37-8 Boc-Arg(Tos)-OH
DownStream 0

Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes.

J. Immunol. 194(7) , 3246-58, (2015)

Despite successful combined antiretroviral therapy, ∼ 60% of HIV-infected people exhibit HIV-associated neurocognitive disorders (HAND). CCL2 is elevated in the CNS of infected people with HAND and me...

Effect of μ-opioid agonist DAMGO on surface CXCR4 and HIV-1 replication in TF-1 human bone marrow progenitor cells.

BMC Res. Notes 7 , 752, (2014)

Approximately one-third of the AIDS cases in the United States have been attributed to the use of injected drugs, frequently involving the abuse of opioids. Consequently, it is critical to address whe...

Dopamine/Tyrosine Hydroxylase Neurons of the Hypothalamic Arcuate Nucleus Release GABA, Communicate with Dopaminergic and Other Arcuate Neurons, and Respond to Dynorphin, Met-Enkephalin, and Oxytocin.

J. Neurosci. 35 , 14966-82, (2015)

We employ transgenic mice with selective expression of tdTomato or cre recombinase together with optogenetics to investigate whether hypothalamic arcuate (ARC) dopamine/tyrosine hydroxylase (TH) neuro...

CYS2,TYR3,ARG5,PEN7-AMIDE

D-Phe-L-Cys-L-Tyr-D-Trp-L-Arg-L-Thr-L-Pen-L-Thr-NH2

M.W. 1104.30 C51H69N13O11S2

1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-10-[3-[(aminoiminomethyl)amino]propyl]-19-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-, (4R,7S,10S,13R,16S,19R)-

cyclic D-Pen-Cys-Tyr-D-Trp-Arg-ThrPen-Thr-NH2

H-D-PHE-CYS-TYR-D-TRP-ARG-THR-PEN-THR-NH2

(7S,10S,13R,16S,19R)-N-[(2S,3R)-1-Amino-3-hydroxy-1-oxo-2-butanyl]-10-(3-carbamimidamidopropyl)-16-(4-hydroxybenzyl)-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

(4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-Amino-3-hydroxy-1-oxo-2-butanyl]-10-(3-carbamimidamidopropyl)-16-(4-hydroxybenzyl)-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2